Vol. 2 No. 12 (2022)
Reimbursement Recommendations

Tezepelumab (Tezspire)

Published December 2, 2022

Key Messages

  • CADTH recommends that Tezspire should be reimbursed by public drug plans for the treatment of severe asthma if certain conditions are met.
  • Tezspire should only be covered to treat patients with severe asthma who are 12 years of age and older if their asthma is not controlled despite using a high dose of inhaled corticosteroids (ICSs) and at least 1 additional medication, and if they have experienced 2 or more asthma exacerbations (also called asthma attacks) that resulted in hospitalization or required treatment with systematic corticosteroids for at least 3 days in the past year.
  • Tezspire should only be reimbursed if prescribed by an allergist or respirologist with experience managing severe asthma and the cost of Tezspire is reduced. Tezspire should not be used in combination with other biologics.